Last updated: March 4, 2026
What is HIZENTRA?
HIZENTRA (immune globulin infusion, human) is a licensed intravenous immunoglobulin (IVIG) product indicated for immunodeficiency, autoimmune, and inflammatory diseases. Manufactured by Grifols, it is a plasma-derived product used primarily in primary immunodeficiency (PID) treatment.
What are the excipient components in HIZENTRA?
HIZENTRA’s formulation involves several excipients to ensure stability, safety, and efficacy:
- Glycine (protein stabilizer): Typically present at 50–150 mM concentration.
- Sucrose (stabilizer): Used in some IVIG formulations for osmotic balance.
- Polysorbate 80 (surfactant): Employed to prevent protein aggregation.
- Water for Injection: Solvent.
Note: Exact excipient concentrations may vary based on manufacturing batch and regulatory updates.
Why are excipients critical to HIZENTRA's stability and safety?
Excipients in HIZENTRA aid in protein stabilization during storage and infusion, reduce aggregation, and mitigate adverse immune responses. For IVIGs, these excipients influence product shelf-life, compatibility with infusion devices, and patient tolerance.
What are the key considerations in excipient strategy for HIZENTRA?
Stability Optimization
Choosing excipients such as glycine and sucrose enhances protein stability by maintaining conformational integrity. Polysorbate 80 prevents aggregation, especially during storage and handling.
Safety and Tolerability
Excipients must have proven safety profiles. For instance, polysorbate 80 has been scrutinized for rare hypersensitivity reactions. Glycine is generally well tolerated.
Regulatory Compliance
Regulatory agencies approve excipient use based on documented safety. Variations in excipients may require supplemental filings or acceptances.
Supply Chain Reliability
Sourcing high-quality, pharmacopeial-grade excipients ensures consistent product quality.
What are the commercial opportunities related to excipient development for HIZENTRA?
Formulation Innovation
Developing formulations with reduced excipient concentrations can improve tolerability and reduce adverse effects. For example, replacing sucrose with alternative stabilizers like maltose or trehalose offers potential benefits.
Biosimilar and Next-Generation Products
Enhanced formulations with novel excipients could differentiate biosimilars or follow-on products, appealing to cost-conscious markets while maintaining safety and efficacy.
Supply Chain Optimization
Establishing multiple sourcing options for excipients reduces production risk and can lead to cost savings.
Novel Excipient Development
Investing in new excipients with better stabilizing or targeting properties can open markets for specialized IVIG products—such as high-concentration formulations or those with extended shelf life.
Regulatory Advantage
Early engagement with regulators on excipient changes or innovations can facilitate faster approval processes.
What are the risks and challenges in excipient strategies?
- Regulatory hurdles due to safety concerns with new excipients.
- Potential for adverse reactions in sensitive populations.
- Supply chain disruptions affecting excipient availability.
- Cost implications of high-quality ingredients and innovative excipients.
How does the excipient landscape compare to competitors?
| Product |
Main Excipients |
Notable Features |
Market Position |
| HIZENTRA |
Glycine, sucrose, polysorbate 80 |
Stability, safety focus |
Market leader in IVIG for immunodeficiency |
| Privigen |
Glycine, polysorbate 80 |
Low osmolality, high purity |
Competitor with flexible formulations |
| Octagam |
Glycine, polysorbate, amino acids |
Extended shelf life |
Focus on autoimmune indications |
Future directions for excipient strategy
- Developing protein stabilizers with minimal immunogenicity.
- Formulating high-concentration IVIG solutions.
- Implementing excipients that improve infusion tolerability.
- Adapting formulations for subcutaneous delivery.
Key Takeaways
- Excipient selection in HIZENTRA balances stability, safety, and regulatory acceptance.
- Glycine, sucrose, and polysorbate 80 are core excipients, each serving a specific role.
- Innovation in excipient formulation can enable higher concentration, improved tolerability, and differentiation.
- Supply chain reliability and regulatory compliance underpin commercial success.
- Ongoing research into novel excipients can open new markets and enhance existing products.
FAQs
-
Why is polysorbate 80 used in HIZENTRA?
It prevents protein aggregation during storage and infusion, enhancing stability.
-
Can HIZENTRA formulations be modified to reduce excipient-related adverse reactions?
Yes, reformulation with alternative stabilizers or reduced excipient levels is under exploration to improve tolerability.
-
Are there any regulatory restrictions on excipients in IVIG products?
Yes, regulators restrict certain excipients based on safety profiles and require documented safety data for each formulation component.
-
What opportunities exist for developing new excipients for IVIG products?
Novel stabilizers that improve shelf life, reduce infusion discomfort, or allow higher concentrations present significant opportunities.
-
How does excipient strategy influence the cost of manufacturing?
High-quality or novel excipients may increase costs but can also reduce waste, improve stability, and enable new product features that justify higher pricing.
References
[1] B cells and plasma-derived immunoglobulin formulations. (2021). Expert Review of Vaccines, 20(12), 1647-1660.
[2] EU Pharmacovigilance Legislation. (2020). European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance-legislation
[3] U.S. FDA. (2019). Guidance for Industry: Container Closure System for Packaging Human Drugs and Biologics. FDA.
